Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine Sequential Regimen for Refractory Lymphoma
NCT02059239Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2014
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), sponsored by Weill Cornell Medicine. Started Jun 2014; status: completed.
02
Drugs
bendamustine
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02059239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059239.